Novavax and Bharat Biotech announce a pandemic influenza vaccine development alliance
Novavax, Inc. and Bharat Biotech International announced a strategic alliance to pursue the rapid development of pandemic influenza vaccine for India and other ASEAN markets. Under the terms of the Agreement, Bharat Biotech will fund all preclinical and clinical development, work with Novavax on optimal manufacturing processes, and be responsible for the commercialization of the vaccine. In return Novavax will receive unrestricted access to all preclinical and clinical data, and a royalty on all sales.
Novavax's Virus Like Particle Technology uses recombinant protein technology to imitate the structure of a virus to provide protection without the risk of infection or disease. Virion proteins can self-assemble into virus-like particles (VLPs) when over-expressed in certain cells. Novavax's proprietary VLP technology produces safe and effective vaccine products through an aseptic process that reduces contamination risk and produces high, cost-effective yields. A key advantage of the technology is the ability to rapidly respond to emerging threats or new strains.
The alliance will be overseen by a steering committee chaired by Dr. Richard Klausner, eminent scientist and Former Executive Director of the Bill and Melinda Gates Foundation and Former Director of the US National Cancer Institute. Dr. Klausner is a special advisor to the Government of India and to Novavax, Inc.
Other news from the department business & finance
